Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. It is grouped under the following drug class(es): Antineoplastic agents, Fertility agents and QTc-prolonging agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Crisafeno and Diemon. Its PubChem CID is 2733526.
Tamoxifen
| CAS No | 10540-29-1 |
|---|---|
| Molecular Formula | C26H29NO |
| Molecular Weight | 371.5 g/mol |
| Synonyms | 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.
The listed CAS number is 10540-29-1.
The listed molecular formula is C26H29NO.
The listed molecular weight is 371.5 g/mol.
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine.
The source lists Crisafeno and Diemon.